Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22788160 | 1.00 | BRD4 (0.32) | BRD4PIK3CD | |
| SCHEMBL14642391 | 0.83 | MAPT (0.32) | BRD4 | |
| SCHEMBL24456545 | 0.83 | — | — | |
| SCHEMBL2029421 | 0.81 | — | — | |
| SCHEMBL10570620 | 0.80 | — | — | |
| SCHEMBL24785956 | 0.79 | MAPK1 (0.32) | PIK3CD | |
| SCHEMBL1717113 | 0.79 | TNKS (0.33) | BRD4 | |
| SCHEMBL12513196 | 0.77 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL12728708 | 0.77 | HTR2B (0.38) | PIK3CD | |
| SCHEMBL22792416 | 0.74 | HTR2B (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0885941-B1 | Ink jet inks containing oxazolidinones | XEROX CORP (US) | 2004-02-18 | — | — | EP | claimed |
| US-5882389-A | WATER, COLOR AND OXAZOLIDINONE | XEROX CORPORATION (US) | 1999-03-16 | — | — | US | claimed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-02 | — | — | US | disclosed |
| US-10954220-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200347033-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2020-11-05 | — | — | US | disclosed |
| US-20190071431-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-0885941-B1 | Ink jet inks containing oxazolidinones | XEROX CORP (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6225370-B1 | FOR USE WITH INK JET PRINTERS | LEXMARK INTERNATIONAL, INC. | 2001-05-01 | — | — | US | disclosed |
| US-5882389-A | WATER, COLOR AND OXAZOLIDINONE | XEROX CORPORATION (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0885941-A1 | Ink jet inks containing oxazolidinones | Xerox Corporation (US) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228535-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | PRSS1, PRSS2, ACE2 | BRD4 685/4885PIK3CD 4023/4885 |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | BRD4 2316/4885PIK3CD 829/4885 |
| US-11634412-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | BRD4 2316/4885PIK3CD 829/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | BRD4 293/4885PIK3CD 1678/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | BRD4 2049/4885PIK3CD 3016/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | BRD4 862/4885PIK3CD 150/4885 |
| US-20190071431-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | BRD4 2316/4885PIK3CD 829/4885 |
| US-11161846-B2 | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators | GRIN2B, GRIN3B, GRIN3A | BRD4 449/4885PIK3CD 2131/4885 |
| US-10954220-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | BRD4 2316/4885PIK3CD 829/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | BRD4 293/4885PIK3CD 1678/4885 |
| US-20230312536-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | BRD4 2316/4885PIK3CD 829/4885 |
| US-20200347033-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, IRF3 | BRD4 2105/4885PIK3CD 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.